2 unknown. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Graves' Disease: new trials by email Literature Review of Graves' Disease trials Research Report on Graves' Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Graves' Disease Remission Study: MycoMeth Combo Mycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg - Graves' Disease | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Xiamen University | 205 | 2023-10-16 | 2024-02-28 |
| Role of the Microbiome in Graves' Orbitopathy LAB4 - Graves' Disease | Phase 1 / Phase 2 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 60 | 2015-02-01 | 2015-02-27 |
Graves Disease (2)
Autoimmune Diseases (2) · Endocrine System Diseases (2) · Exophthalmos (2) · Eye Diseases (2) · Goiter (2) · Hyperthyroidism (2) · Immune System Diseases (2) · Orbital Diseases (2) · Thyroid Diseases (2)
Methimazole (1) · Mycophenolic Acid (1)
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · The First Affiliated Hospital of Xiamen University (1)
China (1) · Italy (1)
Fangsen Xiao, MD (1) · Mario Salvi, MD (1)
PMID 18299459, PMID 26670972, PMID 27272078, PMID 27521067, PMID 27797318, PMID 29396246, PMID 30912336, PMID 32055040, PMID 32616746, PMID 32929476, PMID 34598995, PMID 35223896, PMID 35959915, PMID 36346684